Option chain shows key data for TNF Pharmaceuticals's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for TNF Pharmaceuticals.

TNF Pharmaceuticals (NASDAQ:TNFA) Stock, Option Chain

TNF Pharmaceuticals

MyMD Pharmaceuticals

TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms. MyMD-1 is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B.

TNF Pharmaceuticals Inc

OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, announced the formation of subsidiary OS Drug Conjugates (OSDC). The formation of OSDC coincides with formal strategic options initiatives to create value from the Company's leading-edge, patented silicone dioxide-based, pH sensitive tunable antibody drug conjugates (tADC) &amp; other tunable drug conjugates (tDC) platforms. The Company has initiated discussions with clinical-stage ADC therapeutics companies in the U.S., China and other jurisdictions to form joint ventures (JVs) pairing those companies' clinical-stage assets with certain assets from the tADC and/or tDC platforms and spinning the JVs into standalone public companies. If successful, OS Therapies intends to provide stock dividends of the public JVs to shareholders.
The OST-tADC and OST-tDC technologies are centered around the Company's proprietary next-generation tunable Antibody Drug Conjugate (tADC) and tunable Drug Conjugates (tDC) platforms. These advanced technologies incorporate pH-sensitive silicon-based linkers: SiLinkers&#x2122; to link the targeting antibodies (or antibody fragments) and therapeutic moieties together while coating the entire package with pH sensitive coating. This strategy can release multiple therapeutic agents selectively within the tumor and tumor microenvironment, which have lower pH levels than the rest of the body. This approach aims to maximize the therapeutic effects while minimizing damage to healthy cells.
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.bccresearch.com%2Fmarket-research%2Fpharmaceuticals%2Fantibody-drug-conjugates-markets-report.html%3Fsrsltid%3DAfmBOoqRPnbxc1SPE0lx3HkAmQ-I2X4xd3bWqvtaZu1wAT7gR0oCGUkb&amp;esheet=54212694&amp;newsitemid=20250224482242&amp;lan=en-US&amp;anchor=BCC+Research&amp;index=1&amp;md5=dda6f15610fa07a596439cc152c306cc">BCC Research</a> estimates that the global market for antibody-drug conjugates is estimated to increase from $10.8 billion in 2023 to $47.0 billion by 2029, at a compound annual growth rate (CAGR) of 28.4% from 2024 through 2029.

News

Dividends

OSTX

OS Therapies Launches Subsidiary to Advance Tunable Antibody Drug Conjugates, Plans Stock Dividends for Shareholders

Goldman Sachs analyst Leah Jordan initiates coverage on Smithfield Foods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFD#NASDAQ">SFD</a>) with a Buy rating and announces Price Target of $32.

Price Target

Initiation

Analyst Ratings

Goldman Sachs Initiates Coverage On Smithfield Foods with Buy Rating, Announces Price Target of $32

Barclays analyst David Anderson maintains Tenaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TS#NYSE">TS</a>) with a Overweight and raises the price target from $48 to $50.

Barclays Maintains Overweight on Tenaris, Raises Price Target to $50

HC Wainwright &amp; Co. analyst Vernon Bernardino reiterates Cardiol Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDL#NASDAQ">CRDL</a>) with a Buy and maintains $9 price target.

Reiteration

CRDL

HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target

WIIM

Target Hospitality shares are trading lower after the company announced it lost a key government contract and withdrew its FY25 guidance.

DPZ: -4% &#x7C; <a href="https://www.benzinga.com//node/43908406">Domino's Pizza shares are trading lower after the company reported worse-than-expected Q4 financial results. It also proposed a 15% dividend hike.</a>
&nbsp;
AAPL: -1.5% &#x7C; <a href="https://www.benzinga.com//node/43907712">Apple Commits $500 Billion to US Investment, Focuses on AI and Silicon Innovation</a>
&nbsp;
U: -7% &#x7C; <a href="https://www.benzinga.com//node/43909035">Unity Software shares are trading lower. The company announced a $500 million convertible senior note offering.</a>

Movers

Trading Ideas

AAPL

Market-Moving News for February 24th

HC Wainwright &amp; Co. analyst Robert Burns reiterates ORIC Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORIC#NASDAQ">ORIC</a>) with a Buy and maintains $21 price target.

ORIC

HC Wainwright & Co. Reiterates Buy on ORIC Pharmaceuticals, Maintains $21 Price Target

GDS Holdings shares are trading lower after Jefferies downgraded the stock from Buy to Hold.

RIVN

Rivian Automotive shares are trading lower after B of A Securities downgraded the stock from Neutral to Underperform and cut its price target from $13 to $10.

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) with a Buy and maintains $48 price target.

PRTA

HC Wainwright & Co. Reiterates Buy on Prothena Corp, Maintains $48 Price Target

On February&nbsp;24, 2025, Leidos Holdings, Inc. (the "Company") announced it has entered into an accelerated share repurchase agreement (the "ASR Agreement") to repurchase $500&nbsp;million of the Company's common stock. These repurchases will be conducted under the Company's ongoing share repurchase authorization.
Pursuant to the ASR Agreement, the Company made an initial payment of $500&nbsp;million to the counterparty financial institution on February&nbsp;20, 2025 and received on the same day initial deliveries of approximately 3&nbsp;million shares of the Company's common stock from the counterparty. The final number of shares to be repurchased by the Company will be based on the volume-weighted average stock price of the Company's common stock during the term of the ASR Agreement, less a discount and subject to adjustments pursuant to the terms and conditions of the ASR Agreement. At settlement, under certain circumstances, the counterparty may be required to deliver additional shares of common stock to the Company, or under certain circumstances, the Company may be required to deliver shares of common stock or to make a cash payment, at its election, to the counterparty. The final settlement under the ASR Agreement is expected during the second quarter of 2025, subject to an earlier completion at the counterparty's option.

Buybacks

LDOS

Leidos Announces $500M Accelerated Share Repurchase Agreement, Buys Back 3M Shares, Final Settlement Expected in Q2 2025

Most people assume that crypto's most popular financial instruments are tokens, but index funds are gaining significant traction. In traditional finance (TradFi), index-based funds have historically outperformed single-asset funds in terms of assets under management (AUM), providing investors with diversified exposure while mitigating risk.
While crypto ETFs, particularly <a href="https://www.sec.gov/newsroom/speeches-statements/gensler-statement-spot-bitcoin-011023">Bitcoin ETFs approved by the Securities and Exchange Commission (SEC) in January 2024</a>, have dominated recent market discussions, index funds offer a broader approach to digital asset investing. Instead of relying on the performance of a single asset, index funds track baskets of assets, creating the diversification that investors have long favored in traditional markets. 
In crypto, this approach holds similar potential. Instead of focusing on a single token like Bitcoin or Ethereum, index funds track multiple high-performing digital assets, offering exposure to the broader market while reducing concentration risk. The Bitwise 10 Crypto Index Fund was one of the first such crypto indexes, launched in 2017, and Fidelity and Bloomberg soon followed with its Bloomberg Galaxy Crypto Index in 2018.
As institutional adoption grows, multi-token index funds that take their unique approach to tracking, benchmarking, and reflecting the overall crypto sector could play a key role in bridging traditional investment strategies with the digital asset space.
<h2 class="wp-block-heading">Indexes spare the hassle &#8211; and risk &#8211; of investing in individual coins</h2>
The abundance of information about a coin &#8211; spread across white papers, discussion boards, social media platforms, and messaging apps &#8211; is difficult to keep up with for one coin, let alone the 1000s of digital assets at any given time. While ETFs save investors the inconvenience of buying, storing, and securing $BTC or other coins with forthcoming ETFs, investors must keep up with this real-time information firehose to manage their portfolios.
When there are many ETFs on the market, investors need to sift through piles of information before deciding which one to ultimately purchase. This is burdensome for most retail investors who simply want some exposure to crypto without getting into the technical details.&nbsp;
From this viewpoint, crypto indexes are a much better option: Investors can defer to the collective growth of a handful of top coins, eliminating the need to perform constant, extensive research on any one coin or ETF.
<h2 class="wp-block-heading">Indexes alleviate users from having to trade short-term </h2>
When investing stocks, short-term trading is often necessary. For instance, if you held shares of Nvidia ($NVDA), you might have felt compelled to buy or sell after the stock dropped following the Deepseek announcement.
In contrast, if you are an investor in the S&amp;P 500, which includes $NVDA, you would not need to respond to any market news. You could buy shares in the S&amp;P 500 and count on the overall growth of the market to withstand any changes to a single stock. Such investors can rest easy, knowing that their investment will always be bullish in the long-term (the S&amp;P boasts an average annual return of over <a href="https://www.investopedia.com/ask/answers/042415/what-average-annual-return-sp-500.asp">10% going back to 1957</a>).
Crypto indexes will be attractive in the same way. Instead of having to regularly take action on a specific token position, investors can simply buy shares in a crypto index and leave them untouched for the long-term. In the parlance of the crypto community, they can "hodl." Such investors can count on the continued growth of crypto to take their shares to new heights over time.
<h2 class="wp-block-heading">Indexes protect investors from the risks associated with FOMO </h2>
The fear of missing out (FOMO) is a real problem in crypto. When investors sit on the sidelines and see peers make money from different financial instruments, they may be prone to jump in and make ill-advised decisions.
FOMO is rampant now with meme coins, which Solana has made easier to launch than ever. A few cycles ago, there was also FOMO for non-fungible tokens and even play-and-earn tokens. All of these instruments are highly volatile. For example, the $SQUID token plummeted 99% in <a href="https://www.bbc.com/news/business-59129466">value in a matter of minutes</a>, while once popular NFT collections, <a href="https://www.theguardian.com/sport/2025/jan/14/almost-10000-images-of-tennis-balls-plunge-up-to-90-in-value-as-australian-open-appears-to-ditch-nfts?utm_source=chatgpt.com">such as those of tennis balls by the Australian Open</a>, were down by 90%.&nbsp;
Indexes can prevent investors from risky FOMO-based decision-making because they already have broad exposure. For example, they would not need to invest in meme coins because most popular indexes include Solana, the preferred blockchain for such assets. Similarly, they would not need to purchase any single NFTs because indexes always have Ethereum, the market leading blockchain for them.&nbsp;
Indexes will likewise give investors exposure to other major trends in the future, all without having to buy into individual assets that are highly risky on their own.
<h2 class="wp-block-heading">Indexing your Crypto Exposure&nbsp;</h2>
As crypto investment vehicles evolve, indexes represent the next logical step in providing retail investors with diversified, low-maintenance exposure to the market. While ETFs solve the challenge of buying and storing individual tokens, they still require investors to stay informed about specific assets. Indexes, on the other hand, simplify the investment process by spreading risk across multiple top-performing cryptocurrencies, much like how traditional stock indexes provide long-term stability.
By mitigating the risks of short-term trading and FOMO-driven decisions, indexes offer a more resilient approach to crypto investing. Whether the market shifts toward new trends or faces periods of volatility, indexes allow investors to participate in crypto's overall growth without the burden of constant research and rebalancing. Just as stock indexes have become a cornerstone of traditional investing, crypto indexes are poised to become a preferred vehicle for long-term, diversified exposure to the digital asset space.&nbsp;
Crypto, in short, operates like a book: The best guide is often the index.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

The Rise of Passive Investing: How Crypto is Evolving for Retail Investors

Westlake shares are trading lower after the company reported worse-than-expected Q4 financial results.

Unity Software shares are trading lower. The company announced a $500 million convertible senior note offering.

A. Preview of timsTOF Ultra 2 system with novel Athena Ion Processor (AIP):
- Improves protein group identification in single-cell proteomics (SCP) by 15%-20%, and peptide identifications in SCP by 20%-25%
-Advances immunopeptidomics with 15%-20% more immunopeptide identifications
B. Launch of DeutEx&#x2122; software for hydrogen-deuterium exchange (HDX-MS) analysis
C. OmniScape&#x2122; 2025b: a breakthrough in top-down protein sequencing software
D. Advances in ProteoScape&#x2122; and Glycoproteomics software capabilities
E. Advances in TwinScape&#x2122; for cloud-based, AI-enabled proteomics quality monitoring

BRKR

Bruker Unveils 4D-Proteomics Breakthrough At US HUPO: Enhanced Single-Cell and Immunopeptidomics With timsTOF Ultra 2 And Athena Ion Processor

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Buy and maintains $53 price target.

XENE

HC Wainwright & Co. Reiterates Buy on Xenon Pharmaceuticals, Maintains $53 Price Target

HC Wainwright &amp; Co. analyst Robert Burns reiterates SpringWorks Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>) with a Buy and maintains $74 price target.

SWTX

HC Wainwright & Co. Reiterates Buy on SpringWorks Therapeutics, Maintains $74 Price Target

MCHP

Microchip Technology Launched MPLAB XC Unified Compiler Licenses For Its MPLAB XC8, XC16, XC-DSC and XC32 C Compilers

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.laserphotonics.com%2F&amp;esheet=54212399&amp;newsitemid=20250224082074&amp;lan=en-US&amp;anchor=Laser+Photonics+Corporation&amp;index=1&amp;md5=223dc3d3ec3a60d49aba12f490f75c5b">Laser Photonics Corporation</a> (LPC) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LASE#NASDAQ">LASE</a>), a leading global developer of industrial laser systems for cleaning and other material processing applications, in partnership with its sibling company Fonon Technologies, announced today the receipt of a second order for its <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fonon.us%2Fproducts%2Fdefensetech-mrls-portable-finishing-laser-1020&amp;esheet=54212399&amp;newsitemid=20250224082074&amp;lan=en-US&amp;anchor=DefenseTech+MRLS+Portable+Finishing+Laser&amp;index=3&amp;md5=223a07b9d89ac41eff38d88550ae268c">DefenseTech MRLS Portable Finishing Laser</a> (MF-1020) handheld cleaning system. This order was facilitated once again through their distribution partner, <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fincrediblesupply.com%2F&amp;esheet=54212399&amp;newsitemid=20250224082074&amp;lan=en-US&amp;anchor=Incredible+Supply+%26amp%3B+Logistics&amp;index=4&amp;md5=d2db227391448095ee4cf287ffd15f20">Incredible Supply &amp; Logistics</a> (ISL), an award-winning product distribution and third-party logistics (3PL) company.
The DTMF-1020 air-cooled handheld pulsed laser cleaning system, equipped with dual-axis technology, streamlines maintenance processes. This system will be utilized by the same Navy command in Virginia Beach that ordered the first unit.

Government

Regulations

LASE

Laser Photonics Secures Second Order for DefenseTech MRLS Laser Cleaning System

Earnings

ATCH

Reported Earlier, AtlasClear Holdings Q2 EPS $(1.11) Down From $2.22 YoY, Sales $2.75M

Press Releases

TNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol "TNFA" Effective Before Market Open Today

TNF Pharmaceuticals Prepares to Advance Lead Clinical Program Targeting Age-Related Decline

TNF Pharmaceuticals Announces Strategic Equity Investment Priced at a Premium to Market

TNF Pharmaceuticals Presents Statistically Significant Phase 2a Trial Results for Novel Sarcopenia/Frailty Treatment at Prestigious International Conference

Comments

TNF Pharmaceuticals

TNF Pharmaceuticals (TNFA) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga